|
US8389521B2
(en)
*
|
2007-04-24 |
2013-03-05 |
Ingenium Pharmaceuticals Gmbh |
Inhibitors of protein kinases
|
|
JP5693951B2
(ja)
|
2007-04-24 |
2015-04-01 |
アストラゼネカ エービー |
プロテインキナーゼの阻害剤
|
|
WO2008129080A1
(en)
*
|
2007-04-24 |
2008-10-30 |
Ingenium Pharmaceuticals Gmbh |
4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
|
|
DE112009005041T5
(de)
*
|
2009-07-08 |
2012-09-27 |
Joben Bio-Medical Co., Ltd. |
Verfahren der Extraktzubereitung aus Longankern und die Anwendung des Longankernextrakts
|
|
JP2013107824A
(ja)
*
|
2010-03-17 |
2013-06-06 |
Dainippon Sumitomo Pharma Co Ltd |
新規単環ピリミジン誘導体
|
|
US20130079345A1
(en)
*
|
2010-03-22 |
2013-03-28 |
Bayer Intellectual Property Gmbh |
Pharmaceutically active disubstituted triazine derivatives
|
|
WO2012066065A1
(en)
*
|
2010-11-17 |
2012-05-24 |
Novartis Ag |
Phenyl-heteroaryl amine compounds and their uses
|
|
JP5947818B2
(ja)
*
|
2011-03-02 |
2016-07-06 |
リード ディスカバリー センター ゲーエムベーハー |
薬学的活性化二置換ピリジン誘導体
|
|
CA2826464C
(en)
*
|
2011-03-02 |
2020-07-28 |
Lead Discovery Center Gmbh |
Pharmaceutically active disubstituted triazine derivatives
|
|
EP2699554B1
(en)
*
|
2011-04-19 |
2016-11-02 |
Bayer Intellectual Property GmbH |
Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
|
|
EP2527332A1
(en)
|
2011-05-24 |
2012-11-28 |
Bayer Intellectual Property GmbH |
4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
|
|
TWI555737B
(zh)
|
2011-05-24 |
2016-11-01 |
拜耳知識產權公司 |
含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
|
|
JP5976814B2
(ja)
*
|
2011-09-16 |
2016-08-24 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
スルホキシイミン基を含有する二置換５−フルオロピリミジン誘導体
|
|
EP2755956B1
(en)
*
|
2011-09-16 |
2016-05-18 |
Bayer Intellectual Property GmbH |
2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors
|
|
WO2014060375A2
(en)
*
|
2012-10-18 |
2014-04-24 |
Bayer Pharma Aktiengesellschaft |
5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
|
|
CA2888383A1
(en)
|
2012-10-18 |
2014-04-24 |
Bayer Pharma Aktiengesellschaft |
N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
|
|
CN105102434A
(zh)
*
|
2012-10-18 |
2015-11-25 |
拜耳药业股份公司 |
含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
|
|
CA2891244C
(en)
*
|
2012-11-15 |
2020-12-01 |
Ulrich Lucking |
4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
|
|
US9650340B2
(en)
|
2012-11-15 |
2017-05-16 |
Bayer Pharma Aktiengesellschaft |
5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
|
|
TW201418243A
(zh)
|
2012-11-15 |
2014-05-16 |
Bayer Pharma AG |
含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
|
|
EP3016945B1
(en)
|
2013-07-04 |
2017-05-03 |
Bayer Pharma Aktiengesellschaft |
Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
|
|
WO2015136028A1
(en)
|
2014-03-13 |
2015-09-17 |
Bayer Pharma Aktiengesellschaft |
5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
|
|
US9790189B2
(en)
|
2014-04-01 |
2017-10-17 |
Bayer Pharma Aktiengesellschaft |
Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
|
|
WO2015155197A1
(en)
|
2014-04-11 |
2015-10-15 |
Bayer Pharma Aktiengesellschaft |
Novel macrocyclic compounds
|
|
CA2964696C
(en)
|
2014-10-16 |
2022-09-06 |
Bayer Pharma Aktiengesellschaft |
Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
|
|
WO2016059011A1
(en)
|
2014-10-16 |
2016-04-21 |
Bayer Pharma Aktiengesellschaft |
Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
|
|
CA2980507A1
(en)
|
2015-03-24 |
2016-09-29 |
Public University Corporation Nagoya City University |
Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas
|
|
CA2980493A1
(en)
|
2015-03-24 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
|
|
WO2016150902A1
(en)
|
2015-03-24 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
|
|
ES2728356T3
(es)
|
2015-06-29 |
2019-10-23 |
Astrazeneca Ab |
Derivados de amidas policíclicas como inhibidores de CDK9
|
|
JP6847099B2
(ja)
|
2015-09-29 |
2021-03-24 |
バイエル ファーマ アクチエンゲゼルシャフト |
新規な大環状スルホンジイミン化合物
|
|
ES2819869T3
(es)
|
2015-10-08 |
2021-04-19 |
Bayer Pharma AG |
Nuevos compuestos macrocíclicos modificados
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
ES2900199T3
(es)
|
2017-03-28 |
2022-03-16 |
Bayer Ag |
Novedosos compuestos macrocíclicos inhibidores de PTEFB
|
|
EP3601236A1
(en)
|
2017-03-28 |
2020-02-05 |
Bayer Aktiengesellschaft |
Novel ptefb inhibiting macrocyclic compounds
|
|
MX2020008447A
(es)
|
2018-02-13 |
2020-09-28 |
Bayer Ag |
Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimi doil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de celulas grandes b.
|
|
CA3172328A1
(en)
*
|
2020-03-27 |
2021-09-30 |
Haruhisa Inoue |
Nerve cell degeneration inhibitor
|